Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

Aim: To determine the efficacy and tolerability of sibutramine hydrochloride in obese patients whose type 2 diabetes was poorly controlled on diet alone or with an oral antidiabetic agent

[1]  A. Cooke,et al.  Peptides derived from murine insulin are diabetogenic in both rats and mice, but the disease-inducing epitopes are different: evidence against a common environmental cross-reactivity in the pathogenicity of type 1 diabetes. , 1999, Diabetes.

[2]  Adesh K. Jain,et al.  Sibutramine produces dose-related weight loss. , 1999, Obesity research.

[3]  P. Vague,et al.  Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. , 1999, The American journal of medicine.

[4]  S. Heymsfield,et al.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. , 1999, JAMA.

[5]  R. Klein,et al.  Relation of Glycemic Control to Diabetic Complications and Health Outcomes , 1998, Diabetes Care.

[6]  M. Harris,et al.  Diabetes in America: Epidemiology and Scope of the Problem , 1998, Diabetes Care.

[7]  Roy A Kaplan,et al.  Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study , 1998, Diabetes Care.

[8]  H. Jackson,et al.  Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. , 1998, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[9]  Alain Golay,et al.  Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients , 1998, The Lancet.

[10]  K. Flegal,et al.  Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994 , 1998, Diabetes Care.

[11]  R. Wing,et al.  Lifestyle Intervention in Overweight Individuals With a Family History of Diabetes , 1998, Diabetes Care.

[12]  R. Klein,et al.  Self-Rated Health and Diabetes of Long Duration: The Wisconsin Epidemiologic Study of Diabetic Retinopathy , 1998, Diabetes Care.

[13]  F. Pi‐Sunyer,et al.  The Prevention and Treatment of Obesity: Application to type 2 diabetes , 1997, Diabetes Care.

[14]  R. Newton,et al.  The Comparison of Four Weight Reduction Strategies Aimed at Overweight Diabetic Patients , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[15]  B. Hoogwerf,et al.  Nutrition Principles for the Management off Diabetes and Related Complications , 1994, Diabetes Care.

[16]  A Tremblay,et al.  Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. , 1994, The American journal of cardiology.

[17]  D. Walmsley,et al.  Diabetic Diets and Nutritional Recommendations: What Happens in Real Life? , 1992, Diabetic medicine : a journal of the British Diabetic Association.

[18]  G. Bray,et al.  Fluoxetine treatment of the obese diabetic. , 1992, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[19]  S. Haffner,et al.  Lack of awareness and treatment of hyperlipidemia in type II diabetes in a community survey. , 1989, JAMA.

[20]  W. R. Buckett,et al.  The contribution of metabolites to the rapid and potent down-regulation of rat cortical β-adrenoceptors by the putative antidepressant sibutramine hydrochloride , 1989, Neuropharmacology.

[21]  S. Welle,et al.  The safety and efficacy of a controlled low-energy ('very-low-calorie') diet in the treatment of non-insulin-dependent diabetes and obesity. , 1988, Archives of internal medicine.

[22]  L. Gaal,et al.  Relationship of Body Fat Distribution Pattern to Atherogenic Risk Factors in NIDDM: Preliminary Results , 1988, Diabetes Care.

[23]  R R Wing,et al.  Long-term effects of modest weight loss in type II diabetic patients. , 1987, Archives of internal medicine.

[24]  L. Epstein,et al.  Type II Diabetic Subjects Lose Less Weight Than Their Overweight Nondiabetic Spouses , 1987, Diabetes Care.

[25]  J. Olefsky,et al.  Metabolic Consequences of Very-Low-Calorie Diet Therapy in Obese Non-insulin-dependent Diabetic and Nondiabetic Subjects , 1986, Diabetes.

[26]  E. Nikkilä.  High Density Lipoproteins in Diabetes , 1981, Diabetes.

[27]  Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance , 1979, Diabetes.

[28]  Gary G. Koch,et al.  Average Partial Association in Three-way Contingency Tables: a Review and Discussion of Alternative Tests , 1978 .

[29]  K. M. West.  Diet therapy of diabetes: an analysis of failure. , 1973, Annals of internal medicine.

[30]  S. Shapiro,et al.  An Analysis of Variance Test for Normality (Complete Samples) , 1965 .

[31]  P. Drouin,et al.  Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study , 1998, International Journal of Obesity.

[32]  A. Rissanen,et al.  Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. , 1998, Lancet.

[33]  K. Goa,et al.  Sibutramine. A review of its contribution to the management of obesity. , 1998, Drugs.

[34]  R. Braybrooke,et al.  A single-dose, placebo-controlled, comparative evaluation of the cardiovascular effects of sibutramine and amitriptyline in normal volunteers , 1997 .

[35]  C. Tse,et al.  Assessing Impact of Weight on Quality of Life. , 1995, Obesity research.

[36]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .